Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-24-001383
Filing Date
2024-08-29
Accepted
2024-08-29 17:26:44
Documents
113
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F nymox_20f.htm   iXBRL 20-F 1462276
2 CERTIFICATION nymox_ex12a.htm EX-12.A 12047
3 CERTIFICATION nymox_ex12b.htm EX-12.B 10899
4 CERTIFICATION nymox_ex13a.htm EX-13.A 3631
5 CERTIFICATION nymox_ex13b.htm EX-13.B 3621
  Complete submission text file 0001640334-24-001383.txt   5975187

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nymox-20231231.xsd EX-101.SCH 107294
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20231231_lab.xml EX-101.LAB 316777
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20231231_cal.xml EX-101.CAL 56754
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20231231_pre.xml EX-101.PRE 277915
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20231231_def.xml EX-101.DEF 149734
116 EXTRACTED XBRL INSTANCE DOCUMENT nymox_20f_htm.xml XML 1025249
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 241264937
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)